COVID-19 Knowledge, Attitudes and Practices and Vaccine Acceptability in Rural Western Kenya and an Urban Informal Settlement in Nairobi, Kenya: A Cross-Sectional Survey
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Setting and Design
2.2. Sample Size Calculation
2.3. Study Population
2.4. Data Collection
2.5. Data Analysis
2.6. Ethical Considerations
3. Results
3.1. Household and Participants’ Characteristics
3.2. Knowledge on COVID-19
3.3. Perceived Risk of Getting COVID-19
3.4. Practices
3.5. Vaccine Acceptability and Factors Associated
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A. Study Questionnaire
Interviewer’s name: ____________________ Interviewer’s code: __ __ __ | |||||
Interview date: __ __/__ __/__ __ | |||||
Today’s date | ☐☐/☐☐/☐☐ | DSS Permanent ID | ☐☐/☐☐☐/☐☐/☐☐ | ||
Site: | ☐ Asembo | ☐ Kibera | ☐ Manyatta | ☐ Other, specify__________ |
Appendix A.1. Bio Data
Participant name: | |
Participant UNIQUE ID (DSS ID): | |
Respondent | ≤Self ≤ Proxy |
If proxy, specify the relationship with the participant | ≤Father ≤ Mother ≤ Uncle ≤ Aunt ≤ Other……… |
Age | _______ ≤ years ≤ months (if <1 year) |
Date of birth (MM/DD/YY) | |
Sex | ≤Male ≤ Female |
Phone number of self/HH head |
Appendix A.2. Knowledge, Attitudes and Practices
Sources of COVID-19 Information | |
In the past one week, from which of the following, if any, have you received news and information about COVID-19 (how)? Select all that apply. | 1 = Online sources (websites, social media) 2 = Messaging apps (WhatsApp)/SMS/text messaging 3 = Conversations (in person or phone) 4 = Newspapers 5 = Television 6 = Radio 7 = Others …. Specify |
In the past week, from which of the following, if any, have you received news and information about COVID-19 (who)? Select all that apply. | 1 = Local health workers, clinics, and community organizations 2 = Scientists, doctors, and health experts 3 = World Health Organization (WHO) 4 = Government health authorities or other officials 5 = Politicians 6 = Journalists 7 = Religious leaders 8 = Relatives 9 = Non-relatives |
How much do you trust the following sources?
| 1 = Trust 2 = Somewhat trust 3 = Does not trust |
How much do you trust the following sources?
| 1 = Trust 2 = Somewhat trust 3 = Does not trust |
COVID-19 Knowledge, Attitudes | |
COVID-19 can spread when an infected person coughs or sneezes. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
COVID-19 can spread from person-to-person when people are in close contact with each other. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
A person can become infected with COVID-19 by touching a surface or object that has the virus on it and then touching their mouth, nose, or eyes. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
A person infected with COVID-19 can transmit the virus to others even if they do not have symptoms. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
Eating or touching wild animals could result in COVID-19 infection. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
Only adults need to take precautionary measures to prevent the spread of COVID-19. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
Young people can develop severe illnesses or die from COVID-19. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
COVID-19 virus is real. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
To prevent transmission of COVID-19 it is important to avoid going to crowded places. | ☐ True ☐ False ☐ Don’t know/not sure ☐ Prefers not to answer |
Prevention measures | |
What measures can you adopt to reduce the risk of contracting coronavirus/COVID-19? (Do not read out options—select all that apply) | 1 = Handwashing 2 = Use of hand sanitizers 3 = Keeping physical distance (>1.5M) 4 = Use of face mask 5 = Avoiding travel unless necessary 6 = Avoid crowded places 7 = Staying at home 8 = Get vaccinated 9 = Take medicines or herbs 10 = Other (specify)___________________ |
In the past 7 days, what steps has your community/government taken to curb the spread of the coronavirus in your area (select all that apply)? | 1 = Advised citizens to stay at home 2 = Advised to avoid gatherings 3 = Restricted travel within county 4 = Restricted international travel 5 = Closure of non-essential businesses 6 = Created public awareness and sensitization of the community 7 = Closure of schools and universities 8 = Curfew and lockdown 9 = Established quarantine/isolation centres 10 = Disinfection of public places 11 = Vaccination 12 = Other (specify)__________________ |
Overall, how satisfied are you with the measures your county/national government is taking to combat COVID-19? | 1 = Very satisfied 2 = Moderately satisfied 3 = Satisfied 4 = Moderately dissatisfied 5 = Very dissatisfied 6 = Neither satisfied or dissatisfied 7 = Don’t know 8 = Prefers not to say |
Prevention measures practices | |
Which of the following measures are you currently taking or have tried to take in the past 7 days (select all that apply)? | 1 = Handwashing 2 = Use of hand sanitizers 3 = Keeping physical distance (>1.5M) 4 = Use of face mask 5 = Avoiding travel unless necessary 6 = Avoiding crowded places 7 = Staying at home 8 = No measures taken 9 = Prefers not to say 10 = Other (specify)___________________ |
In the past 7 days (Q26–Q29): | |
When you clean your hands, how often are you able to clean your hands with soap or alcohol based hand sanitizer? | 1 = Never 2 = Sometimes 3 = Always |
How often are you able to stay at least 1.5 m (arm’s length) away from people outside your household? | 1 = Never 2 = Sometimes 3 = Always |
How often do you wear a mask or facecovering when you are in public? | 1 = Never 2 = Sometimes 3 = Always |
How often do you stay at home? | 1 = Never (1) 2 = Rarely (2) 3 = Sometimes (3) 4 = Often (4) 5 = Always (5) |
In the past 7 days, did you attend any social gatherings with family or friends? | ☐ Yes ☐ No ☐ Not sure ☐ Prefers not to answer |
In the past 7 days, did you leave the house to go to work or to attend school? | ☐ Yes ☐ No ☐ Not sure ☐ Prefers not to answer |
If you tested positive for COVID-19 or think you might have COVID-19, how possible would it be for you to:
| 1 to 4 with 1 being very difficult and 4 being with ease |
Perceived risk | |
How dangerous do you think COVID-19 is a risk to your community? | 1 = Not at all dangerous 2 = Moderately dangerous 3 = Extremely dangerous 4 = Prefer not to answer |
How worried are you about contracting COVID-19? | 1 = Not at all worried 2 = Somewhat worried Very worried 3 = Prefer not to answer |
Vaccine awareness and acceptability | |
| ☐ Yes ☐ No ☐ Not sure ☐ Prefers not to answer |
| 1 = Yes, definitely 2 = No, definitely not 3 = Not sure/Don’t know 4 = Not answered |
If “no, definitely not” or “not sure/don’t know”,
| 1 = Concerned over side effects and/or safety 2 = Concerned that it won’t be effective at preventing COVID-19 3 = I do not need it/I am not at risk 4 = Underlying health condition/ineligible to receive it 5 = The cost 6 = Concerned the vaccine can cause COVID-19 7 = I don’t believe in the vaccine/COVID-19 8 = God’s will if I get sick 9 = I don’t have enough information to decide 10 = Other (specify)____________________ 11 = Prefer not to answer |
Impact of COVID-19 | |
How worried are you about not having enough food in your household? | 1 = Not at all worried Somewhat worried 2 = Greatly worried 3 = Prefer not to answer |
If worried (a little, somewhat, or greatly), Since COVID-19 has been in Kenya (March 2020), has your worry about not having enough food in your household… | 1 = Increased a lot 2 = Increased a little 3 = Decreased a lot 4 = Decreased a little 5 = Stayed the same (no difference) |
How has your work changed since COVID-19 has been in Kenya (March 2020)? | 1 = No longer employed (1) 2 = Newly employed (2) 3 = Employed in a different business (3) 4 = Role substantially changed with same business (4) 5 = Little or no change (5) |
Since COVID-19 has been in Kenya (March 2020), have you lost earnings because of the virus or because of the restrictions? | ☐ Yes ☐ No ☐ Not sure ☐ Prefers not to answer |
If yes, What are the main areas of expenditure if any that you have had to reduce, delay, or eliminate altogether? (multiple responses up to three) | 1 = Food 2 = Clothing/goods 3 = Transportation 4 = Rent 5 = Entertainment 6 = Assistance to others 7 = Repayment of loans 8 = Cooking fuel School fees 9 = Electricity/water 10 = Alcohol 11 = Medicines/treatment 12 = Air-time 13 = No changes 14 = Don’t know 15 = Prefers not to answer 16 = Other .. specify |
Anxiety | |
In the last 2 weeks, how often have you been bothered by the following problems? Feeling nervous or anxious Not being able to stop or control worrying Worrying/thinking too much about different things Trouble relaxing Being so restless that it is hard to sit still Becoming easily annoyed or irritable Feeling afraid as if something awful might happen | 1 = Not at all 2 = Several days 3 = More than half the days 4 = Nearly every day |
References
- WHO. Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int (accessed on 10 August 2021).
- Nasimiyu, C.; Matoke-Muhia, D.; Rono, G.K.; Osoro, E.; Ouso, D.O.; Mwangi, J.M.; Mwikwabe, N.; Thiong’o, K.; Dawa, J.; Ngere, I.; et al. Imported SARS-CoV-2 Variants of Concern Drove Spread of Infections across Kenya during the Second Year of the Pandemic. COVID 2022, 2, 586–598. [Google Scholar] [CrossRef]
- Gueye, K.; Padane, A.; Diédhiou, C.K.; Ndiour, S.; Diagne, N.D.; Mboup, A.; Mbow, M.; Lo, C.I.; Leye, N.; Ndoye, A.S.; et al. Evolution of SARS-CoV-2 Strains in Senegal: From a Wild Wuhan Strain to the Omicron Variant. COVID 2022, 2, 1116–1124. [Google Scholar] [CrossRef]
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
- Quaife, M.; van Zandvoort, K.; Gimma, A.; Shah, K.; McCreesh, N.; Prem, K.; Barasa, E.; Mwanga, D.; Kangwana, B.; Pinchoff, J.; et al. The impact of COVID-19 control measures on social contacts and transmission in Kenyan informal settlements. BMC Med. 2020, 18, 1–11. [Google Scholar] [CrossRef]
- COVID-19 for Africa: Lockdown Exit Strategies|United Nations Economic Commission for Africa. Available online: https://www.uneca.org/covid-19-africa-lockdown-exit-strategies (accessed on 27 July 2021).
- Kitara, D.L.; Ikoona, E.N. COVID-19 pandemic, Uganda’s story. Pan Afr. Med. J. 2020, 35, 51. [Google Scholar] [CrossRef]
- Azlan, A.A.; Hamzah, M.R.; Sern, T.J.; Ayub, S.H.; Mohamad, E. Public knowledge, attitudes and practices towards COVID-19: A cross-sectional study in Malaysia. PLoS ONE 2020, 15, e0233668. [Google Scholar] [CrossRef]
- COVID-19 Vaccines: Everything You Need to Know. Available online: https://www.gavi.org/covid19-vaccines (accessed on 15 June 2021).
- McNamara, D. Delta Variant Could Drive “Herd Immunity” Threshold over 80%. Available online: https://www.webmd.com/lung/news/20210803/delta-variant-could-drive-herd-immunity-threshold-over-80 (accessed on 23 September 2021).
- Kenya Receives COVID-19 Vaccines and Launches Landmark National Campaign. Available online: https://www.afro.who.int/news/kenya-receives-covid-19-vaccines-and-launches-landmark-national-campaign (accessed on 12 May 2022).
- Ministry of Health—Republic of Kenya. Available online: https://www.health.go.ke/ (accessed on 9 June 2021).
- Murewanhema, G.; Dzinamarira, T.; Chingombe, I.; Mapingure, M.P.; Mukwenha, S.; Chitungo, I.; Herrera, H.; Madziva, R.; Ngwenya, S.; Musuka, G. Emerging SARS-CoV-2 Variants, Inequitable Vaccine Distribution, and Implications for COVID-19 Control in Sub-Saharan Africa. COVID 2022, 2, 341–349. [Google Scholar] [CrossRef]
- Orangi, S.; Pinchoff, J.; Mwanga, D.; Abuya, T.; Hamaluba, M.; Warimwe, G.; Austrian, K.; Barasa, E. Assessing the level and determinants of COVID-19 Vaccine Confidence in Kenya. Vaccines 2021, 9, 936. [Google Scholar] [CrossRef]
- Ocholla, B.A.; Nyangena, O.; Murayi, H.K.; Mwangi, J.W.; Belle, S.K.; Ondeko, P.; Kendagor, R. Association of Demographic and Occupational Factors with SARS-CoV-2 Vaccine Uptake in Kenya. Open Access Libr. J. 2021, 8, 1–8. [Google Scholar] [CrossRef]
- Reuben, R.C.; Danladi, M.M.A.; Saleh, D.A.; Ejembi, P.E. Knowledge, Attitudes and Practices Towards COVID-19: An Epidemiological Survey in North-Central Nigeria. J. Community Health 2020, 46, 457–470. [Google Scholar] [CrossRef]
- Nwagbara, U.I.; Osual, E.C.; Chireshe, R.; Bolarinwa, O.A.; Saeed, B.Q.; Khuzwayo, N.; Hlongwana, K.W. Knowledge, attitude, perception, and preventative practices towards COVID-19 in sub-Saharan Africa: A scoping review. PLoS ONE 2021, 16, e0249853. [Google Scholar] [CrossRef] [PubMed]
- Feikin, D.R.; Olack, B.; Bigogo, G.M.; Audi, A.; Cosmas, L.; Aura, B.; Burke, H.; Njenga, M.K.; Williamson, J.; Breiman, R.F. The Burden of Common Infectious Disease Syndromes at the Clinic and Household Level from Population-Based Surveillance in Rural and Urban Kenya. PLoS ONE 2011, 6, e16085. [Google Scholar] [CrossRef]
- Uyoga, S.; Adetifa, I.M.O.; Karanja, H.K.; Nyagwange, J.; Tuju, J.; Wanjiku, P.; Aman, R.; Mwangangi, M.; Amoth, P.; Kasera, K.; et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 2021, 371, 79–82. [Google Scholar] [CrossRef]
- Malani, A.; Shah, D.; Kang, G.; Lobo, G.N.; Shastri, J.; Mohanan, M.; Jain, R.; Agrawal, S.; Juneja, S.; Imad, S.; et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. Lancet Glob. Health 2021, 9, e110–e111. [Google Scholar] [CrossRef]
- 2020 Year End Survey: Festive Season Plans and COVID-19 Issues. TIFA Research 2020. Available online: http://www.tifaresearch.com/2020-year-end-survey-festive-season-plans-and-covid19-issues/ (accessed on 28 June 2022).
- Ministry-of-Health-Kenya-Covid-19-Immunization-Status-Report-17th-January-2022. Available online: https://www.health.go.ke/wp-content/uploads/2022/01/MINISTRY-OF-HEALTH-KENYA-COVID-19-IMMUNIZATION-STATUS-REPORT-17TH-JANUARY-2022.pdf (accessed on 12 May 2022).
- Feleke, B.T.; Wale, M.Z.; Yirsaw, M.T. Knowledge, attitude and preventive practice towards COVID-19 and associated factors among outpatient service visitors at Debre Markos compressive specialized hospital, north-west Ethiopia, 2020. PLoS ONE 2021, 16, e0251708. [Google Scholar] [CrossRef] [PubMed]
- White, H. A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. Econometrica 1980, 48, 817–838. [Google Scholar] [CrossRef]
- Huber, P.J. The Behavior of Maximum Likelihood Estimates under Nonstandard Conditions. 1967. Available online: https://www.academia.edu/52597492/The_behavior_of_maximum_likelihood_estimates_under_nonstandard_conditions (accessed on 8 June 2022).
- Habib, M.A.; Dayyab, F.M.; Iliyasu, G.; Habib, A.G. Knowledge, attitude and practice survey of COVID-19 pandemic in Northern Nigeria. PLoS ONE 2021, 16, e0245176. [Google Scholar] [CrossRef]
- Kenya_basic_Education_COVID-19_Emergency_Response_Plan-compressed. Available online: https://www.education.go.ke/images/Kenya_basic_Education_COVID-19_Emergency_Response_Plan-compressed (accessed on 19 July 2022).
- Lewis. Keeping Children in Nairobi Informal Settlement Safe from COVID-19. Kenya Community Media Network 2021. Available online: https://kcomnet.org/keeping-children-in-nairobi-informal-settlement-safe-from-covid-19/ (accessed on 19 July 2022).
- Aguilar Ticona, J.P.; Nery, N.; Victoriano, R.; Fofana, M.O.; Ribeiro, G.S.; Giorgi, E.; Reis, M.G.; Ko, A.I.; Costa, F. Willingness to Get the COVID-19 Vaccine among Residents of Slum Settlements. Vaccines 2021, 9, 951. [Google Scholar] [CrossRef]
- Abedin, M.; Islam, M.A.; Rahman, F.N.; Reza, H.M.; Hossain, M.Z.; Hossain, M.A.; Arefin, A.; Hossain, A. Willingness to vaccinate against COVID-19 among Bangladeshi adults: Understanding the strategies to optimize vaccination coverage. PLoS ONE 2021, 16, e0250495. [Google Scholar] [CrossRef]
- Al-Mohaithef, M.; Padhi, B.K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J. Multidiscip. Healthc. 2020, 13, 1657–1663. [Google Scholar] [CrossRef]
- Cooper, S.; van Rooyen, H.; Wiysonge, C.S. COVID-19 vaccine hesitancy in South Africa: How can we maximize uptake of COVID-19 vaccines? Expert Rev. Vaccines 2021, 20, 921–933. [Google Scholar] [CrossRef] [PubMed]
- Bhopal, S.S.; Bagaria, J.; Olabi, B.; Bhopal, R. Children and young people remain at low risk of COVID-19 mortality. Lancet Child Adolesc. Health 2021, 5, e12–e13. [Google Scholar] [CrossRef]
- Society, C.P. Canadian Study Confirms Children and Youth at Low Risk of Severe COVID-19 during First Part of Pandemic|Canadian Paediatric Society. Available online: https://cps.ca/en/media/canadian-study-confirms-children-and-youth-at-low-risk-of-severe-covid-19-during-first-part-of-pandemic (accessed on 28 June 2022).
- Snape, M.D.; Viner, R.M. COVID-19 in children and young people. Science 2020, 370, 286–288. [Google Scholar] [CrossRef] [PubMed]
- Karijo, E.; Wamugi, S.; Lemanyishoe, S.; Njuki, J.; Boit, F.; Kibui, V.; Karanja, S.; Abuya, T. Knowledge, attitudes, practices, and the effects of COVID-19 among the youth in Kenya. BMC Public Health 2021, 21, 1020. [Google Scholar] [CrossRef]
- Nyadera, I.N.; Onditi, F. COVID-19 experience among slum dwellers in Nairobi: A double tragedy or useful lesson for public health reforms? Int. Soc. Work. 2020, 63, 838–841. [Google Scholar] [CrossRef]
- Nuwematsiko, R.; Nabiryo, M.; Bomboka, J.B.; Nalinya, S.; Musoke, D.; Okello, D.; Wanyenze, R.K. Unintended socio-economic and health consequences of COVID-19 among slum dwellers in Kampala, Uganda. BMC Public Health 2022, 22, 88. [Google Scholar] [CrossRef]
- The Health of People Who Live in Slums. Available online: https://www.thelancet.com/series/slum-health (accessed on 27 September 2021).
- Auerbach, A.M.; Thachil, T. How Does COVID-19 Affect Urban Slums? Evidence from Settlement Leaders in India. World Dev. 2021, 140, 105304. [Google Scholar] [CrossRef]
- Pinho, A.C. AstraZeneca’s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Platelets. Available online: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (accessed on 20 June 2021).
- Adverse Effects from Covid Jab Reported in Kenya—Kagwe. Available online: https://www.the-star.co.ke/news/2021-04-06-277-adverse-effects-from-covid-jab-reported-in-kenya-kagwe/ (accessed on 22 July 2021).
- Ray, S.U.K. Reports 30 Cases of Rare Blood Clots Linked to AstraZeneca Vaccine, Insists Benefits Outweigh Any Risks. Available online: https://www.forbes.com/sites/siladityaray/2021/04/02/uk-reports-30-cases-of-rare-blood-clots-linked-to-astrazeneca-vaccine-insists-benefits-outweigh-any-risks/ (accessed on 22 July 2021).
- Wirsiy, F.S.; Nkfusai, C.N.; Ako-Arrey, D.E.; Dongmo, E.K.; Manjong, F.T.; Cumber, S.N. Acceptability of COVID-19 Vaccine in Africa. Int. J. Matern. Child Health AIDS 2021, 10, 134–138. [Google Scholar] [CrossRef]
- Akiful Haque, M.M.; Rahman, M.L.; Hossian, M.; Matin, K.F.; Nabi, M.H.; Saha, S.; Hasan, M.; Manna, R.M.; Barsha, S.Y.; Hasan, S.M.R.; et al. Acceptance of COVID-19 vaccine and its determinants: Evidence from a large sample study in Bangladesh. Heliyon 2021, 7, e07376. [Google Scholar] [CrossRef]
- Paul, A.; Sikdar, D.; Mahanta, J.; Ghosh, S.; Jabed, M.A.; Paul, S.; Yeasmin, F.; Sikdar, S.; Chowdhury, B.; Nath, T.K. Peoples’ understanding, acceptance, and perceived challenges of vaccination against COVID-19: A cross-sectional study in Bangladesh. PLoS ONE 2021, 16, e0256493. [Google Scholar] [CrossRef]
- Murthy, B.P. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties—United States, December 14, 2020–April 10, 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 759. [Google Scholar] [CrossRef] [PubMed]
- Luyten, J.; Bruyneel, L.; van Hoek, A.J. Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. Vaccine 2019, 37, 2494–2501. [Google Scholar] [CrossRef] [PubMed]
- Hudson, A.; Montelpare, W.J. Predictors of Vaccine Hesitancy: Implications for COVID-19 Public Health Messaging. Int. J. Environ. Res. Public Health 2021, 18, 8054. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Categories | Asembo, N = 458 | Kibera, N = 398 | |
---|---|---|---|---|
n (%) | n (%) | p-Value | ||
Age in years (y) | 18–29 y | 127 (27.7) | 145 (36.4) | <0.0001 |
30–39 y | 106 (23.1) | 115 (28.9) | ||
40–49 y | 75 (16.4) | 81 (20.4) | ||
50–59 y | 57 (12.5) | 43(10.8) | ||
≥60 y | 93 (20.3) | 14 (3.5) | ||
Sex | Male | 166 (36.0) | 136 (34.2) | 0.527 |
Female | 292 (63.8) | 262 (65.8) | ||
Marital status | Married | 265 (57.9) | 260 (65.7) | <0.0001 |
Single | 103 (22.5) | 111 (28.0) | ||
Previously married * | 90 (19.7) | 25 (5.5) | ||
Education | None | 29 (6.3) | 5 (1.3) | <0.0001 |
Incomplete primary | 135 (29.5) | 51 (12.8) | ||
Complete primary | 107 (23.4) | 113 (28.4) | ||
Incomplete secondary | 95 (20.7) | 67 (16.8) | ||
Complete secondary | 60 (13.1) | 100 (25.1) | ||
Post-secondary | 32 (7.0) | 60 (15.1) | ||
Missing | 0 | 2(0.5) | ||
Occupation | Unemployed | 173 (37.7) | 138 (34.7) | <0.0001 |
Employed formal | 17 (3.7) | 26 (6.5) | ||
Employed informal | 32 (7.2) | 88 (22.1) | ||
Self-employed | 210 (45.6) | 139 (34.9) | ||
Missing | 26 (5.7) | 7 (1.8) |
Knowledge Questions ** | Asembo n = 458 | Kibera n = 398 | p-Value |
---|---|---|---|
n (%) | n (%) | ||
| 441 (96.2) | 385 (96.5) | 0.84 |
| 445 (97.5) | 386 (86.3) | 0.39 |
| 431 (95.3) | 381 (94.6) | 0.67 |
| 396 (88.3) | 343 (86.0) | 0.40 |
| 418 (91.2) | 356 (89.3) | 0.44 |
| 420 (92.8) | 349 (87.2) | 0.03 * |
| 449 (97.8) | 370 (91.6) | 0.001 * |
| 446 (98.1) | 392 (97.4) | 0.55 |
Characteristics | Asembo | Kibera | ||
---|---|---|---|---|
Odds Ratio (95% CI) | p-Value | Odds Ratio (95% CI) | p-Value | |
Age | ||||
18–29 yrs | Ref | Ref | ||
30–39 yrs | 1.96 (0.16–23.73) | 0.595 | 1.02 (0.21–4.89) | 0.984 |
40–49 yrs | 5.79 (0.48–69.53) | 0.165 | 0.86 (0.14–5.41) | 0.873 |
50–59 yrs | 1.32 (0.12–14.27) | 0.820 | 3.76 (0.22–64.73) | 0.361 |
60+ yrs ** | 1.79 (0.23–14.21) | 0.579 | ||
Sex | ||||
Female | Ref | Ref | ||
Male | 0.59 (0.13–2.72) | 0.498 | 0.27 (0.07–1.04) | 0.058 |
Occupation | ||||
Unemployed | Ref | Ref | ||
Employed | 0.98 (0.06–17.42) | 0.990 | 2.31 (0.39–13.62) | 0.355 |
Self-employed | 0.57 (0.13–2.49) | 0.455 | 1.88 (0.37–9.68) | 0.447 |
Education | ||||
None/Primary | Ref | Ref | ||
Secondary | 3.88 (0.52–29.00) | 0.186 | 4.02 (1.23–13.16) * | 0.022 |
Post-secondary | 2.19 (0.49–9.78) | 0.304 | 4.01 (0.34–47.82) | 0.271 |
Marital status | ||||
Single | Ref | Ref | ||
Married | 1.89 (0.40–9.07) | 0.423 | 0.61 (0.06–5.73) | 0.661 |
Divorced/separated ** | 0.48 (0.01–15.89) | 0.682 | ||
Widowed | 0.46 (0.08–2.64) | 0.379 | 0.43 (0.01–13.11) | 0.624 |
Characteristics | Asembo | Kibera | ||
---|---|---|---|---|
Odds Ratio (95% CI) | p-Value | Odds Ratio (95% CI) | p-Value | |
Age | ||||
18–29 yrs | Ref | Ref | ||
30–39 yrs | 1.22 (0.42–3.58) | 0.714 | 2.19 (0.92–5.18) | 0.076 |
40–49 yrs | 0.73 (0.21–2.50) | 0.614 | 3.32 (1.37–8.03) | 0.008 * |
50–59 yrs | 0.70 (0.14–3.58) | 0.662 | 3.64 (1.15–11.49) | 0.028 * |
60+ yrs | 0.27 (0.07–0.98) | 0.047 * | 2.69 (0.41–17.57) | 0.301 |
Sex | ||||
Female | Ref | Ref | ||
Male | 0.87 (0.34–2.18) | 0.759 | 0.66 (0.34–1.29) | 0.224 |
Occupation | ||||
Unemployed | Ref | Ref | ||
Employed formal | 0.85 (0.19–3.88) | 0.832 | 0.18 (0.05–0.68) | 0.011 * |
Employed informal | 2.17 (0.28–16.68) | 0.454 | 0.56 (0.23–1.40) | 0.218 |
Self employed | 1.69 (0.82–3.47) | 0.154 | 0.34 (0.15–0.77) | 0.010 * |
Education | ||||
None | Ref | Ref | ||
Primary | 0.95 (0.33–2.78) | 0.927 | 1.84 (0.19–17.83) | 0.598 |
Secondary | 0.71 (0.20–2.49) | 0.592 | 1.15 (0.12–10.95) | 0.903 |
Post-secondary | 0.52 (0.11–2.50) | 0.417 | 5.75 (0.51–65.31) | 0.157 |
Marital status | ||||
Single | Ref | Ref | ||
Married | 0.75 (0.20–2.83) | 0.665 | 0.95 (0.42–2.15) | 0.906 |
Divorced/separated Widowed | 0.62 (0.13–3.05) | 0.553 | 0.78 (0.14–4.21) | 0.772 |
COVID-19 Prevention Practice | Asembo (N = 458) | Kibera (N = 398) | p-Value |
---|---|---|---|
n (%) | n (%) | ||
Handwashing | 438 (94.8) | 381 (94.6) | 0.936 |
Use of hand sanitizers | 144 (34.1) | 303 (75.5) | <0.0001 * |
Keeping physical distance (>1.5 m) | 286 (64.4) | 306 (76.5) | 0.002 * |
Use of face mask | 426 (91.7) | 378 (94.4) | 0.221 |
Avoiding travel unless necessary | 119 (27.3) | 263 (65.6) | <0.0001 * |
Avoiding crowded places | 323 (72.6) | 293 (72.2) | 0.918 |
Staying at home | 88 (19.4) | 200 (48.7) | <0.0001 * |
Number of mitigation measures practiced | |||
<2 | 9 (2.0) | 5 (2.0) | <0.0001 * |
2–4 | 296 (62.8) | 118 (30.0) | |
≥5 | 153 (35.2) | 275 (68.0) |
Characteristics | Asembo | Kibera | ||
---|---|---|---|---|
Odds Ratio (95% CI) | p-Value | Odds Ratio (95% CI) | p-Value | |
Age | ||||
18–29 yrs | Ref | Ref | ||
30–39 yrs | 0.76 (0.28–2.08) | 0.596 | 0.89 (0.46–1.71) | 0.726 |
40–49 yrs | 0.68 (0.23–1.94) | 0.465 | 0.99 (0.47–2.09) | 0.987 |
50–59 yrs | 0.91 (0.26–3.24) | 0.888 | 2.59 (0.93–7.24) | 0.069 |
60+ yrs | 0.68 (0.22–2.08) | 0.494 | 2.35 (0.50–11.01) | 0.278 |
Sex | ||||
Female | Ref | Ref | ||
Male | 1.10 (0.60–2.04) | 0.752 | 1.41 (0.80–2.48) | 0.231 |
Occupation | ||||
Unemployed | Ref | Ref | ||
Employed | 0.51 (0.19–1.39) | 0.187 | 0.90 (0.47–1.74) | 0.750 |
Self employed | 1.39 (0.64–3.03) | 0.408 | 1.14 (0.62–2.10) | 0.664 |
Education | ||||
None/Primary | Ref | Ref | ||
Secondary | 0.79 (0.34–1.82) | 0.580 | 0.64 (0.37–1.12) | 0.119 |
Post-secondary | 0.69 (0.25–1.89) | 0.465 | 0.40 (0.18–0.85) | 0.018 * |
Marital status | ||||
Single | Ref | Ref | ||
Married | 1.94 (0.78–4.86) | 0.155 | 1.19 (0.61–2.34) | 0.610 |
Divorced/separated. | 0.68 (0.12–3.91) | 0.666 | 1.16 (0.24–5.56) | 0.856 |
Widowed | 0.84 (0.21–3.30) | 0.801 | 2.88 (0.53–15.69) | 0.219 |
Knowledge scores | ||||
Good | Ref | Ref | ||
Poor | 0.62 (0.11–3.30) | 0.577 | 0.52 (0.18–1.47) | 0.215 |
COVID-19 Risk | ||||
Not Dangerous | Ref | Ref | ||
Dangerous | 0.41 (0.10–1.73) | 0.226 | 3.88 (0.35–43.61) | 0.271 |
COVID-19 Worry | ||||
Not Worried | Ref | Ref | ||
Worried | 0.95 (0.36–2.47) | 0.909 | 1.60 (0.89–2.86) | 0.114 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nasimiyu, C.; Audi, A.; Oduor, C.; Ombok, C.; Oketch, D.; Aol, G.; Ouma, A.; Osoro, E.; Ngere, I.; Njoroge, R.; et al. COVID-19 Knowledge, Attitudes and Practices and Vaccine Acceptability in Rural Western Kenya and an Urban Informal Settlement in Nairobi, Kenya: A Cross-Sectional Survey. COVID 2022, 2, 1491-1508. https://doi.org/10.3390/covid2100107
Nasimiyu C, Audi A, Oduor C, Ombok C, Oketch D, Aol G, Ouma A, Osoro E, Ngere I, Njoroge R, et al. COVID-19 Knowledge, Attitudes and Practices and Vaccine Acceptability in Rural Western Kenya and an Urban Informal Settlement in Nairobi, Kenya: A Cross-Sectional Survey. COVID. 2022; 2(10):1491-1508. https://doi.org/10.3390/covid2100107
Chicago/Turabian StyleNasimiyu, Carolyne, Allan Audi, Clifford Oduor, Cynthia Ombok, Dismas Oketch, George Aol, Alice Ouma, Eric Osoro, Isaac Ngere, Ruth Njoroge, and et al. 2022. "COVID-19 Knowledge, Attitudes and Practices and Vaccine Acceptability in Rural Western Kenya and an Urban Informal Settlement in Nairobi, Kenya: A Cross-Sectional Survey" COVID 2, no. 10: 1491-1508. https://doi.org/10.3390/covid2100107
APA StyleNasimiyu, C., Audi, A., Oduor, C., Ombok, C., Oketch, D., Aol, G., Ouma, A., Osoro, E., Ngere, I., Njoroge, R., Munyua, P., Lo, T., Herman-Roloff, A., Bigogo, G., & Munywoki, P. K. (2022). COVID-19 Knowledge, Attitudes and Practices and Vaccine Acceptability in Rural Western Kenya and an Urban Informal Settlement in Nairobi, Kenya: A Cross-Sectional Survey. COVID, 2(10), 1491-1508. https://doi.org/10.3390/covid2100107